Overton’s nomination withdrawal means no clear end for FDA leadership vacuum

The White House’s abrupt withdrawal of Heidi Overton as President Trump’s nominee to lead the Food and Drug Administration (FDA) means the agency will remain without stable leadership six months after the former commissioner resigned, leaving industry observers anxious. The Trump administration’s…
This is a brief. The reporting belongs to The Hill — read the complete story, with full context and credits, at the source.
Read the full story at The Hill ↗thehill.com
More from the Health desk

Virginia child dies in state’s first measles-associated death of 2026
Princess Catherine reflects on cancer journey in new documentary

Independent review ordered into surgery carried out by NHS Grampian
